Trial · NCT03142334
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Disease-free Survival (DFS) as Assessed by the Investigator | Up to approximately 42 months (database cutoff date 14 Dec 2020) | All randomized participants | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) | Up to approximately 72 months | |||
| SECONDARY | Number of Participants Who Experienced an Adverse Event (AE) | Nonserious AEs: Up to 30 days after last dose of study treatment (Up to approximately 13 months); Serious AEs: Up to 90 days after last dose of study treatment (Up to approximately 15 months) | |||
| SECONDARY | Number of Participants Who Discontinued Study Drug Due to an AE | Up to approximately 12 months | |||
| SECONDARY | First Local Disease Recurrence-specific Survival (DRSS1) as Assessed by the Investigator | Up to approximately 72 months | |||
| SECONDARY | Second Disease Recurrence-Specific Survival (DRSS2) as Assessed by the Investigator | Up to approximately 72 months | |||
| SECONDARY | Event-Free Survival (EFS) as Assessed by the Blinded Independent Central Review (BICR) | Up to approximately 72 months | |||
| SECONDARY | DFS According to Participant Programmed Cell Death-Ligand 1 (PD-L1) Expression Status (Positive, Negative) as Assessed by the Investigator | Up to approximately 72 months | |||
| SECONDARY | OS According to Participant PD-L1 Expression Status (Positive, Negative) | Up to approximately 72 months | |||
| SECONDARY | Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) Total Score | Baseline and Week 52 | |||
| SECONDARY | Change From Baseline in the Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Index Score | Baseline and Week 52 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03142334/outcomes